WNT6

Summary

WNT6 (Wnt family member 6, HGNC:12785) is a protein-coding gene on chromosome 2q35, encoding Protein Wnt-6 (Q9Y6F9). Ligand for members of the frizzled family of seven transmembrane receptors.

The WNT gene family consists of structurally related genes which encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. This gene is a member of the WNT gene family. It is overexpressed in cervical cancer cell line and strongly coexpressed with another family member, WNT10A, in colorectal cancer cell line. The gene overexpression may play key roles in carcinogenesis. This gene and the WNT10A gene are clustered in the chromosome 2q35 region. The protein encoded by this gene is 97% identical to the mouse Wnt6 protein at the amino acid level.

Source: NCBI Gene 7475 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 48 total — 1 pathogenic
• MANE Select transcript: NM_006522

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12785
Approved symbol	WNT6
Name	Wnt family member 6
Location	2q35
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000115596
Ensembl biotype	protein_coding
OMIM	604663
Entrez	7475

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000233948, ENST00000486233

RefSeq mRNA: 1 — MANE Select: NM_006522 NM_006522

CCDS: CCDS2425

Canonical transcript exons

ENST00000233948 — 4 exons

Exon	Start	End
ENSE00000922341	218871027	218871247
ENSE00000922342	218871485	218871819
ENSE00000922343	218873384	218874233
ENSE00001075206	218859805	218860117

Expression profiles

Bgee: expression breadth ubiquitous, 152 present calls, max score 96.46.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3048 / max 115.2853, expressed in 307 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
25402	0.5114	181
25403	0.4817	183
25401	0.3117	98

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	96.46	gold quality
tibial nerve	UBERON:0001323	86.76	gold quality
Brodmann (1909) area 10	UBERON:0013541	83.01	gold quality
frontal pole	UBERON:0002795	82.84	gold quality
sural nerve	UBERON:0015488	82.31	gold quality
middle frontal gyrus	UBERON:0002702	80.30	gold quality
paraflocculus	UBERON:0005351	80.09	gold quality
putamen	UBERON:0001874	76.07	gold quality
apex of heart	UBERON:0002098	75.20	gold quality
caudate nucleus	UBERON:0001873	74.38	gold quality
muscle layer of sigmoid colon	UBERON:0035805	74.15	gold quality
decidua	UBERON:0002450	74.06	gold quality
cerebellar vermis	UBERON:0004720	72.46	gold quality
spleen	UBERON:0002106	71.17	gold quality
olfactory bulb	UBERON:0002264	71.10	gold quality
sigmoid colon	UBERON:0001159	70.99	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	70.67	gold quality
nucleus accumbens	UBERON:0001882	70.32	gold quality
lower esophagus muscularis layer	UBERON:0035833	70.23	gold quality
lower esophagus	UBERON:0013473	70.12	gold quality
tongue squamous epithelium	UBERON:0006919	70.00	gold quality
mucosa of stomach	UBERON:0001199	69.96	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	69.79	gold quality
endocervix	UBERON:0000458	68.49	gold quality
ectocervix	UBERON:0012249	67.75	gold quality
heart left ventricle	UBERON:0002084	67.49	gold quality
triceps brachii	UBERON:0001509	67.12	gold quality
cardiac ventricle	UBERON:0002082	67.06	gold quality
left uterine tube	UBERON:0001303	67.01	gold quality
gluteal muscle	UBERON:0002000	66.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.75

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXA2, GATA6

miRNA regulators (miRDB)

11 targeting WNT6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-6784-3P	98.39	64.88	662
HSA-MIR-6862-3P	97.92	64.86	531
HSA-MIR-2861	95.24	65.47	1056

Literature-anchored findings (GeneRIF, showing 17)

• Wnt6 plays an important role in tooth development by promoting human dental papilla cell differentiation, without significant effects on cell proliferation. (PMID:20113781)
• The WNT6 rs6747776 homozygous minor allele (CC) was associated with increased risk of colorectal adenoma. (PMID:21547848)
• WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs (PMID:22370641)
• WNT6 activates the JNK signaling pathway in HDPCs, leading to migration and differentiation. (PMID:24935540)
• analysis of missense mutation in WNT6 in couples with unexplained recurrent miscarriage (PMID:25750203)
• our results support the concept that WNT6 may play a role in tumor progression (PMID:26617869)
• The authors show that WNT6 is significantly overexpressed in glioblastoma, as compared to lower-grade gliomas and normal brain, at mRNA and protein levels. Functionally, WNT6 increases typical oncogenic activities in glioblastoma cells, including viability, proliferation, glioma stem cell capacity, invasion, migration, and resistance to temozolomide chemotherapy. (PMID:30279739)
• WNT6 may be a diagnostic and prognostic marker in osteosarcoma (PMID:30431574)
• Study results indicated that PLAGL2 was overexpressed in colorectal cancer (CRC) as a protooncogene and that it could active the Wnt/betacatenin pathway as a transcription factor by binding with the promoter region of Wnt6. (PMID:30535429)
• Secreted Wnt6 binds to FZD4 to activate the canonical Wnt6 signaling pathway, which is upstream of ROCK1 and 14-3-3sigma, and that this is the cell signaling pathway underlying diabetes-associated centrosome amplification. (PMID:31618077)
• A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. (PMID:31923345)
• MiR-566 protects the malignant progression of breast cancer by negatively regulating WNT6. (PMID:32572884)
• Wnt6 plays a complex role in maintaining human limbal stem/progenitor cells. (PMID:34686698)
• Wnt4, Wnt6 and beta-catenin expression in human placental tissue - is there a link with first trimester miscarriage? Results from a pilot study. (PMID:35300692)
• The glycoprotein Wnt6 regulates human dental papilla cells differentiation by canonical Wnt signaling pathway. (PMID:35691114)
• WNT6 participates in the occurrence and development of ovarian cancer by upregulating/activating the typical Wnt pathway and Notch1 signaling pathway. (PMID:36075327)
• The investigation of WNT6 and WNT10A single nucleotide polymorphisms as potential biomarkers for dental pulp calcification in orthodontic patients. (PMID:37566620)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	wnt6b	ENSDARG00000073935
mus_musculus	Wnt6	ENSMUSG00000033227
rattus_norvegicus	Wnt6	ENSRNOG00000017409
drosophila_melanogaster	Wnt6	FBGN0031902

Paralogs (18): WNT16 (ENSG00000002745), WNT8A (ENSG00000061492), WNT8B (ENSG00000075290), WNT11 (ENSG00000085741), WNT2 (ENSG00000105989), WNT3 (ENSG00000108379), WNT5B (ENSG00000111186), WNT5A (ENSG00000114251), WNT1 (ENSG00000125084), WNT2B (ENSG00000134245), WNT10A (ENSG00000135925), WNT9A (ENSG00000143816), WNT3A (ENSG00000154342), WNT7A (ENSG00000154764), WNT9B (ENSG00000158955), WNT4 (ENSG00000162552), WNT10B (ENSG00000169884), WNT7B (ENSG00000188064)

Protein

Protein identifiers

Protein Wnt-6 — Q9Y6F9 (reviewed: Q9Y6F9)

All UniProt accessions (1): Q9Y6F9

UniProt curated annotations — full annotation on UniProt →

Function. Ligand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. May be a signaling molecule which affects the development of discrete regions of tissues. Is likely to signal over only few cell diameters. Together with CAV1 may promote chemoresistance of gastric cancer cells to DNA-damaging anthracycline drugs through the activation of the canonical Wnt receptor signaling pathway.

Subunit / interactions. Interacts with PORCN.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Expressed in gastric cancer cell lines and gastric cancer tissues (at protein level). Detected in the apical gland region of the gastric foveolar epithelium (at protein level).

Post-translational modifications. Palmitoleoylation is required for efficient binding to frizzled receptors. Depalmitoleoylation leads to Wnt signaling pathway inhibition.

Similarity. Belongs to the Wnt family.

RefSeq proteins (1): NP_006513* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005817	Wnt	Family
IPR009143	Wnt6	Family
IPR018161	Wnt_CS	Conserved_site
IPR043158	Wnt_C	Homologous_superfamily

Pfam: PF00110

UniProt features (18 total): disulfide bond 11, glycosylation site 2, signal peptide 1, chain 1, region of interest 1, compositionally biased region 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6F9-F1	83.62	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 228

Disulfide bonds (11): 222–236, 224–231, 294–325, 310–320, 324–364, 340–355, 342–352, 347–348, 76–87, 124–132, 134–172

Glycosylation sites (2): 86, 311

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-3238698	WNT ligand biogenesis and trafficking
R-HSA-373080	Class B/2 (Secretin family receptors)

MSigDB gene sets: 224 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, RNGTGGGC_UNKNOWN, GOBP_EPITHELIUM_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, GOBP_AXIS_SPECIFICATION, KEGG_HEDGEHOG_SIGNALING_PATHWAY, GOBP_CELLULAR_RESPONSE_TO_LIPID, GCANCTGNY_MYOD_Q6, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, GOCC_CELL_SURFACE, GOBP_NEUROGENESIS, TAL1ALPHAE47_01, GOBP_KIDNEY_EPITHELIUM_DEVELOPMENT, GOBP_TOOTH_MINERALIZATION, GGGTGGRR_PAX4_03

GO Biological Process (16): branching involved in ureteric bud morphogenesis (GO:0001658), axis specification (GO:0009798), positive regulation of gene expression (GO:0010628), neuron differentiation (GO:0030182), odontogenesis of dentin-containing tooth (GO:0042475), cell fate commitment (GO:0045165), positive regulation of DNA-templated transcription (GO:0045893), canonical Wnt signaling pathway (GO:0060070), epithelial-mesenchymal cell signaling (GO:0060684), cornea development in camera-type eye (GO:0061303), positive regulation of tooth mineralization (GO:0070172), cellular response to retinoic acid (GO:0071300), nephron tubule formation (GO:0072079), multicellular organism development (GO:0007275), Wnt signaling pathway (GO:0016055), nephron tubule development (GO:0072080)

GO Molecular Function (3): frizzled binding (GO:0005109), cytokine activity (GO:0005125), signaling receptor binding (GO:0005102)

GO Cellular Component (9): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), endoplasmic reticulum lumen (GO:0005788), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), cell surface (GO:0009986), endocytic vesicle membrane (GO:0030666), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by WNT	1
GPCR ligand binding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell differentiation	2
anatomical structure development	2
cellular anatomical structure	2
intracellular organelle lumen	2
branching morphogenesis of an epithelial tube	1
ureteric bud morphogenesis	1
pattern specification process	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
generation of neurons	1
odontogenesis	1
cellular developmental process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
Wnt signaling pathway	1
cell-cell signaling	1
camera-type eye development	1
tooth mineralization	1
positive regulation of biomineral tissue development	1
regulation of tooth mineralization	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
embryonic epithelial tube formation	1
nephron tubule morphogenesis	1
multicellular organismal process	1
cell surface receptor signaling pathway	1
renal tubule development	1
nephron epithelium development	1
G protein-coupled receptor binding	1
receptor ligand activity	1
protein binding	1
endoplasmic reticulum	1
Golgi apparatus	1
membrane	1
cell periphery	1
endocytic vesicle	1
cytoplasmic vesicle membrane	1

Protein interactions and networks

STRING

1250 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WNT6	DKK2	Q9UBU2	874
WNT6	DKK3	Q9UBP4	865
WNT6	FZD2	Q14332	864
WNT6	DKK4	Q9UBT3	860
WNT6	DKK1	O94907	847
WNT6	LRP5	O75197	814
WNT6	FZD9	O00144	787
WNT6	FZD4	Q9ULV1	762
WNT6	FZD1	Q9UP38	753
WNT6	FZD5	Q13467	748
WNT6	FZD3	Q9NPG1	724
WNT6	SFRP1	Q8N474	719
WNT6	LRP6	O75581	706
WNT6	FZD6	O60353	697
WNT6	FZD7	O75084	691

IntAct

6 interactions, top by confidence:

A	B	Type	Score
NOTCH2	ZNF316	psi-mi:“MI:0914”(association)	0.530
WNT6	CHEK1	psi-mi:“MI:0914”(association)	0.350
C1orf54	QSOX1	psi-mi:“MI:0914”(association)	0.350
LYPD1	ADAM10	psi-mi:“MI:0914”(association)	0.350
PATE1	AGRN	psi-mi:“MI:0914”(association)	0.350
WNT3A	LRP5	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): WNT6 (Reconstituted Complex), WNT6 (Co-localization), SEC11A (Affinity Capture-MS), SPCS1 (Affinity Capture-MS), SEC11C (Affinity Capture-MS), SPCS2 (Affinity Capture-MS), CHEK1 (Affinity Capture-MS)

ESM2 similar proteins: D3Z7H8, D3ZE55, D3ZT86, G7PWZ3, O00634, O08644, O15197, O15230, O88516, O88671, O95206, P00744, P07204, P0C0K6, P0C0K7, P20863, P22727, P24347, P27539, P43029, P58459, P98161, P98167, Q04912, Q2PC93, Q3UH93, Q3UQ22, Q5IJ48, Q5JZY3, Q5W7P8, Q61001, Q6MG84, Q71U07, Q76LX8, Q7TSK3, Q80YA8, Q86UP0, Q8BYG9, Q8TE56, Q8WTR8

Diamond homologs: A0M8S1, A0M8T2, A1X153, A4D7S0, B2GUT4, O00755, O13267, O15978, O42122, O70283, P04426, P04628, P09544, P09615, P10108, P17553, P21551, P21552, P22724, P22725, P22726, P22727, P24257, P24383, P27467, P28047, P28465, P31285, P31286, P33945, P34888, P34889, P41221, P43446, P47793, P49337, P49338, P49339, P49340, P49893

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
WNT6	up-regulates	FZD3	binding
WNT6	up-regulates	LRP5	binding
WNT6	up-regulates	CTNNB1
WNT6	up-regulates	MYOD1
WNT6	up-regulates	MYF5

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	41
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1459325	NC_000002.11:g.(?219646906)(219738567_?)del	Pathogenic

SpliceAI

634 predictions. Top by Δscore:

Variant	Effect	Δscore
2:218871023:CCA:C	acceptor_loss	1.0000
2:218871024:CA:C	acceptor_loss	1.0000
2:218871025:A:AG	acceptor_gain	1.0000
2:218871025:AG:A	acceptor_gain	1.0000
2:218871025:AGG:A	acceptor_gain	1.0000
2:218871026:G:GG	acceptor_gain	1.0000
2:218871026:GG:G	acceptor_gain	1.0000
2:218871026:GGG:G	acceptor_gain	1.0000
2:218871026:GGGC:G	acceptor_gain	1.0000
2:218871026:GGGCT:G	acceptor_gain	1.0000
2:218871230:G:GT	donor_gain	1.0000
2:218871246:GG:G	donor_gain	1.0000
2:218871247:GG:G	donor_gain	1.0000
2:218871483:A:AG	acceptor_gain	1.0000
2:218871484:G:GA	acceptor_gain	1.0000
2:218871484:GAC:G	acceptor_gain	1.0000
2:218871815:GGCTG:G	donor_gain	1.0000
2:218871816:GCTGG:G	donor_gain	1.0000
2:218871023:CCAGG:C	acceptor_gain	0.9900
2:218871024:CAGG:C	acceptor_gain	0.9900
2:218871025:AGGG:A	acceptor_gain	0.9900
2:218871243:ACAGG:A	donor_gain	0.9900
2:218871245:AGGG:A	donor_loss	0.9900
2:218871247:GGT:G	donor_loss	0.9900
2:218871248:G:GG	donor_gain	0.9900
2:218871248:G:T	donor_gain	0.9900
2:218871248:GT:G	donor_loss	0.9900
2:218871249:T:G	donor_loss	0.9900
2:218871479:TCACA:T	acceptor_loss	0.9900
2:218871480:CACA:C	acceptor_loss	0.9900

AlphaMissense

2329 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:218871201:G:C	W85C	1.000
2:218871201:G:T	W85C	1.000
2:218873777:T:C	F344L	1.000
2:218873778:T:G	F344C	1.000
2:218873779:C:A	F344L	1.000
2:218873779:C:G	F344L	1.000
2:218873785:G:C	W346C	1.000
2:218873785:G:T	W346C	1.000
2:218871199:T:A	W85R	0.999
2:218871199:T:C	W85R	0.999
2:218871562:G:T	G127C	0.999
2:218871690:G:C	W169C	0.999
2:218871690:G:T	W169C	0.999
2:218871801:C:A	N206K	0.999
2:218871801:C:G	N206K	0.999
2:218871811:G:T	G210C	0.999
2:218873416:A:C	K223N	0.999
2:218873416:A:T	K223N	0.999
2:218873417:T:A	C224S	0.999
2:218873418:G:C	C224S	0.999
2:218873458:G:C	W237C	0.999
2:218873458:G:T	W237C	0.999
2:218873475:T:G	F243C	0.999
2:218873625:T:G	F293C	0.999
2:218873771:T:A	C342S	0.999
2:218873772:G:C	C342S	0.999
2:218873778:T:C	F344S	0.999
2:218871172:T:A	C76S	0.998
2:218871173:G:C	C76S	0.998
2:218871206:G:A	C87Y	0.998

dbSNP variants (sampled 300 via entrez): RS1000805740 (2:218870565 G>A,T), RS1000900154 (2:218861142 G>C), RS1000925958 (2:218861510 T>C), RS1000939744 (2:218870300 A>G), RS1000974096 (2:218874646 G>A), RS1001088908 (2:218867508 G>A), RS1001128147 (2:218863771 C>A,T), RS1001140940 (2:218872294 G>C), RS1001269714 (2:218867744 C>T), RS1001276552 (2:218872048 G>T), RS1001373465 (2:218865544 C>A,T), RS1001433881 (2:218864008 G>T), RS1001638733 (2:218858787 A>G), RS1001874697 (2:218869316 A>C,G), RS1001897234 (2:218862463 A>T)

Disease associations

OMIM: gene MIM:604663 | disease phenotypes: MIM:213700, MIM:600057

GenCC curated gene-disease

Mondo (2): cerebrotendinous xanthomatosis (MONDO:0008948), bladder exstrophy-epispadias-cloacal exstrophy complex (MONDO:0700039)

Orphanet (2): Cerebrotendinous xanthomatosis (Orphanet:909), Classic bladder exstrophy (Orphanet:93930)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST006661_114	Male-pattern baldness	2.000000e-16
GCST008839_251	Height	4.000000e-09
GCST011345_32	Triglyceride levels	4.000000e-08
GCST011348_45	High density lipoprotein cholesterol levels	1.000000e-14
GCST90002405_2	Reticulocyte count	5.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007986	reticulocyte count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D019294	Xanthomatosis, Cerebrotendinous	C16.320.565.398.925; C18.452.584.563.925; C18.452.584.750.975; C18.452.648.398.925

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
Tetrachlorodibenzodioxin	increases expression	3
Acetaminophen	decreases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
ETC-159	decreases expression	1
methyleugenol	decreases expression	1
propionaldehyde	decreases expression	1
trichostatin A	increases expression	1
beta-lapachone	decreases expression	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, decreases reaction	1
mercuric bromide	affects cotreatment, increases expression	1
dinophysistoxin 1	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
theaflavin-3,3’-digallate	affects expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Panobinostat	affects cotreatment, increases expression	1
Microplastics	increases abundance, increases expression	1
Cadmium	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Formaldehyde	increases expression	1
Hydrogen Peroxide	affects expression	1
Lipopolysaccharides	decreases expression, decreases reaction	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7W3	SEES3-1V human WNT6, clone1	Embryonic stem cell	Male
CVCL_A7W4	SEES3-1V human WNT6, clone2	Embryonic stem cell	Male
CVCL_A7W5	SEES3-1V human WNT6, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

10 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04270682	PHASE3	COMPLETED	Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
NCT00004346	PHASE2	UNKNOWN	Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
NCT00018694	Not specified	WITHDRAWN	Cholestanol in Humans
NCT00935389	Not specified	COMPLETED	Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
NCT01613898	Not specified	UNKNOWN	Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis
NCT02638220	Not specified	COMPLETED	Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
NCT02699190	Not specified	COMPLETED	LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT03047369	Not specified	RECRUITING	The Myelin Disorders Biorepository Project
NCT03584893	Not specified	UNKNOWN	The Prevalence of CTX Disorder in Juvenile Cataract Cases in Turkey
NCT05368038	Not specified	ENROLLING_BY_INVITATION	ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program